Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience

BACKGROUND:Peripheral T/NK–cell lymphomas (PTCL) are a heterogeneous group of neoplasms with a median survival of 2-3 years. Currently, there is not standard treatment although consolidation of response with autologous stem cell transplantation (ASCT) is recommended as front line therapy, except in anaplastic ALK+ and T/NK nasal localized lymphomas.